(LNTH) Lantheus Holdings, Inc. BCG Matrix Research

In FY2025, PYLARIFY stayed Lantheus Holdings, Inc.'s Star, with U.S. use expanding across oncology sites, hospitals, and outpatient centers as physicians became more familiar with PSMA PET and payer coverage broadened. The brand's scale matters because each added scan helps defend share and supports durable cash generation.

• Broad U.S. site expansion.
• More physician familiarity.
• Wider payer coverage.
• Share retention drives cash flow.

PYLARIFY’s non-U.S. model is partner-led, so Lantheus can scale without building a full local sales force. That matters because PSMA PET adoption outside the U.S. is still early, but the addressable market is expanding as more systems and reimbursement paths open. In 2025, this kind of asset-light expansion helps keep margins cleaner while extending franchise peak value.

• Partner-based distribution lowers fixed cost risk
• Early PSMA PET adoption supports high growth
• International reach can lengthen peak sales

RELISTOR is Lantheus Holdings, Inc.'s branded methylnaltrexone for opioid-induced constipation, a mature niche with limited growth but steady demand. In Lantheus Holdings, Inc.'s FY2025 reporting, it fits the Cash Cow bucket because the brand is established, needs modest incremental promotion, and can keep converting prescription volume into cash flow.

• Established branded therapy
• Mature, low-growth market
• Cash flow with light promotion

DEFINITY remains Lantheus Holdings, Inc.’s cash cow: it holds a leading share in echocardiography contrast and serves a broad, steady hospital and outpatient base. Its mature installed demand profile makes revenue less volatile, and that scale helps Lantheus generate dependable operating cash for R&D and new launches.

• Leading echocardiography contrast franchise
• Broad clinical use, steady demand
• Mature scale supports operating cash

Cobalt-57 is a small legacy radiochemical within Lantheus Holdings, Inc. and fits the Dogs bucket: limited commercial scale, low growth, and weak strategic pull. Lantheus reported FY2025 revenue of about $1.5 billion, but it does not break out Cobalt-57 sales, which itself signals a minor line. In BCG terms, it is more likely a cash trap than a growth engine.

• Legacy radiochemical
• Minimal disclosed scale
• Low-growth profile
• Likely cash trap

AZEDRA remains a niche therapeutic for rare pheochromocytoma/paraganglioma use, so its commercial reach is still limited inside Lantheus Holdings, Inc. It has not scaled into a broad revenue engine, which fits a BCG Dog: low market penetration, modest growth, and weak contribution versus the Company Name’s larger growth platforms.

• Specialty use, narrow patient pool
• Limited revenue traction
• Low share in its market
• BCG Dog classification

LMI 1195 fits the "Question Mark" box in the BCG Matrix: it targets neuroblastoma, a rare pediatric cancer with about 600 U.S. cases a year, but it still has little commercial footprint. Pediatric oncology imaging and therapy remain high-need niches, so the asset has clear upside if Lantheus converts clinical data into adoption. For now, it is promising but still too early to drive meaningful sales.

• High unmet need, low current revenue
• Rare disease = small launch base
• Upside depends on clinical proof

Leronlimab is an investigational monoclonal antibody partnered with CytoDyn, so Lantheus Holdings, Inc. has no recorded commercial share from the asset yet. Its late-stage path is still uncertain, and that makes it a classic BCG Question Mark: high potential, low visibility.

With no approved revenue stream and no disclosed 2026 market sales for Lantheus, the asset remains speculative rather than a proven cash generator.

• Investigational, not commercialized
• Partnered with CytoDyn
• No market share for Lantheus
• High upside, high risk